Table 1:

Formulary list date and dates of mandatory biosimilar switching policies (if applicable) for biosimilar insulin glargine, infliximab and etanercept for the included provinces

Drug	Alberta	British Columbia	Manitoba	New Brunswick	Nova Scotia	Ontario	Prince Edward Island	Quebec	Saskatchewan
Biosimilar insulin glargine
List date	10/2017	08/2018	10/2018	10/2017^*	11/2017^*	08/2017	09/2017^*	08/2017	01/2018
Biosimilar switch period	12/2019 to 02/2021	05/2019 to 11/2019	NA	04/2021 to 11/2021	02/2022 to 02/2023	NA	NA	04/2022	NA
Biosimilar infliximab
New start	04/2016	02/2016	04/2016	06/2016	06/2016	02/2016	06/2016	02/2017	05/2016^†
Biosimilar switch period	12/2019 to 02/2021	05/2019 to 11/2019	NA	04/2021 to 11/2021	02/2022 to 02/2023	NA	NA	04/2022	NA
Biosimilar etanercept
New start	09/2017	07/2017	04/2018	10/2017	11/2017	07/2017	09/2017	08/2017	10/2017
Biosimilar switch period	12/2019 to 02/2021	05/2019 to 11/2019	NA	04/2021 to 11/2021	02/2022 to 02/2023	NA	NA	04/2022	NA

Note: NA = not applicable.
↵* Special authority was required for the originator drug but not the biosimilar drug.
↵† Naive access to originator drug permitted.